Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Daniela Žáčková · SciRah

Researcher profile · Semantic Scholar

Daniela Žáčková

Share profile

Daniela Žáčková — researcher profile on SciRah

h-index: 16
Works: 127
Citations: 824

Most-cited papers

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Verena S. Hoffmann, M. Baccarani, J. Hasford, F. Castagnetti +29 more
2017Leukemia98 citations Open access
Semantic Scholar
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
M. Pfirrmann, R. Clark, W. Prejzner, M. Lauseker +26 more
2020Leukemia77 citations Open access
Semantic Scholar
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia
Z. Ráčil, F. Rázga, J. Drápalová, L. Buresova +6 more
2013Haematologica77 citations Open access
Semantic Scholar
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects
M. Čulen, M. Borsky, V. Némethová, F. Rázga +12 more
2016OncoTarget38 citations Open access
Semantic Scholar
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
A. Brioli, E. Lomaia, C. Fabisch, Tomasz Sacha +34 more
2024Leukemia28 citations Open access
Semantic Scholar
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
J. Richter, A. Lübking, S. Söderlund, K. Lotfi +15 more
2021Leukemia27 citations Open access
Semantic Scholar
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
M. Lauseker, Katharina Bachl, A. Turkina, E. Faber +18 more
2019American journal of hematology/oncology27 citations Open access
Semantic Scholar
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
Katerina Machova Polakova, H. Žižková, J. Zuna, E. Motlova +19 more
2020Leukemia26 citations Open access
Semantic Scholar
Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
J. Voglová, Jan Mužík, Edgar Faber, Daniela Žáčková +10 more
2011Neoplasma (Bratislava)26 citations
Semantic Scholar
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
Matthew Salmon, H. White, H. Žižková, A. Gottschalk +29 more
2022Leukemia24 citations Open access
Semantic Scholar
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
A. Hochhaus, A. Burchert, S. Saussele, G. Baerlocher +23 more
2023Blood20 citations Open access
Semantic Scholar
Considerations for Treatment‐free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
G. Saglio, Giora Sharf, A. Almeida, A. Bogdanović +8 more
2018Clinical Lymphoma, Myeloma & Leukemia20 citations Open access
Semantic Scholar
Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?
Daniela Žáčková, H. Klamová, L. Dušek, J. Mužík +14 more
2011American journal of hematology/oncology19 citations Open access
Semantic Scholar
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
P. Bělohlávková, F. Vrbacký, J. Voglová, Z. Ráčil +5 more
2018Archives of medical science : AMS18 citations Open access
Semantic Scholar
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
M. Perusini, Daniela Žáčková, TaeHyung Kim, K. Pagnano +18 more
2024Blood Advances17 citations Open access
Semantic Scholar
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy
Z. Ráčil, E. Koriťáková, T. Sacha, H. Klamová +11 more
2018American journal of hematology/oncology17 citations Open access
Semantic Scholar
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
F. Efficace, F. Mahon, J. Richter, A. Piciocchi +20 more
2024Leukemia16 citations Open access
Semantic Scholar
Elucidation of protein interactions necessary for the maintenance of the BCR–ABL signaling complex
Tomas Gregor, M. Bosakova, Alexandru Nita, Sara P. Abraham +8 more
2019Cellular and Molecular Life Sciences15 citations Open access
Semantic Scholar
Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types
Z. Ráčil, F. Rázga, K. Polakova, L. Buresova +6 more
2011Leukemia and Lymphoma14 citations
Semantic Scholar
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia
F. Rázga, Z. Ráčil, Katerina Machova Polakova, L. Buresova +6 more
2011International journal of hematology12 citations
Semantic Scholar
Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
Racil Zdenek, P. Bělohlávková, P. Cetkovský, E. Faber +7 more
201410 citations
Semantic Scholar
BCR‐ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next‐generation sequencing
M. Musilová, F. Rázga, T. Jurček, I. Ježíšková +7 more
2014American journal of hematology/oncology10 citations Open access
Semantic Scholar
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
T. Pavlík, E. Janousová, Z. Pospíšil, J. Mužík +7 more
2011BMC Medical Research Methodology10 citations Open access
Semantic Scholar
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Katerina Machova Polakova, A. Albeer, V. Polívková, Monika Krutska +33 more
2023Leukemia8 citations Open access
Semantic Scholar
Novel Illumina‐based next generation sequencing approach with one‐round amplification provides early and reliable detection of BCR‐ABL1 kinase domain mutations in chronic myeloid leukemia
M. Romzova, Dagmar Smitalova, N. Tom, T. Jurček +4 more
2020British Journal of Haematology7 citations
Semantic Scholar
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
Z. Ráčil, F. Rázga, H. Klamová, J. Voglová +11 more
2014Hematological Oncology7 citations
Semantic Scholar
Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
F. Rázga, T. Jurček, Daniela Žáčková, D. Dvorakova +4 more
2012Molecular Diagnosis & Therapy7 citations
Semantic Scholar
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
P. Bělohlávková, Daniela Žáčková, H. Klamová, Edgar Faber +10 more
2024Cancer Medicine6 citations Open access
Semantic Scholar
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study
T. Horňák, L. Semerád, Daniela Žáčková, B. Weinbergerová +9 more
2020Leukemia and Lymphoma6 citations
Semantic Scholar
COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study
K. Pagnano, C. Kok, M. Mauro, Jorge E. Cortes +9 more
2021Blood5 citations Open access
Semantic Scholar
Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
T. Pavlík, E. Janousová, J. Mayer, K. Indrák +17 more
2013American journal of hematology/oncology5 citations
Semantic Scholar
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
T. Horňák, Jiří Mayer, Petra Čičátková, L. Semerád +23 more
2024American journal of hematology/oncology4 citations Open access
Semantic Scholar
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
Andrea Knight, Martin Piskacek, M. Jurajda, J. Procházková +3 more
2022Cancer Immunology and Immunotherapy4 citations Open access
Semantic Scholar
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow‐up
M. Romzova, Dagmar Smitalova, J. Hynšt, N. Tom +8 more
2021British Journal of Haematology4 citations Open access
Semantic Scholar
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Daniela Žáčková, L. Semerád, Edgar Faber, H. Klamová +25 more
2024Leukemia3 citations Open access
Semantic Scholar
Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy
M. Perusini, Camille Kockerols, Daniela Žáčková, F. Nicolini +15 more
2023Blood3 citations
Semantic Scholar
Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission
Daniela Žáčková, E. Faber, L. Stejskal, M. Karas +19 more
2021Blood3 citations Open access
Semantic Scholar
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
Daniela Žáčková, H. Klamová, P. Bělohlávková, L. Stejskal +11 more
2020Leukemia and Lymphoma3 citations
Semantic Scholar
The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia
M. Pfirrmann, J. Hasford, S. Saussele, A. Turkina +12 more
20153 citations
Semantic Scholar
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels
H. Klamová, K. Polakova, J. Mužík, Z. Ráčil +23 more
2013Cancer Medicine3 citations Open access
Semantic Scholar
Ponatinib for CML patients in routine clinical practice: the PONDEROSA study
T. Schenk, C. Fabisch, T. Ernst, Philipp Ernst +5 more
2026Annals of Hematology2 citations Open access
Semantic Scholar
Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib
T. Horňák, Daniela Žáčková, Jiří Mayer
2025Annals of Hematology2 citations Open access
Semantic Scholar
Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
M. Perusini, Camille Kockerols, Daniela Žáčková, F. Nicolini +23 more
2024Blood2 citations
Semantic Scholar
A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
J. Radich, C. Kok, E. Chelysheva, J. Cortes +11 more
2022Blood2 citations Open access
Semantic Scholar
Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia
TaeHyung Kim, Daniela Žáčková, I. Ježíšková, Anežka Kvetková +9 more
2022Blood2 citations Open access
Semantic Scholar
Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence
T. Dahlén, Camille Kockerols, G. Ferreira, P. Westerweel +5 more
2021Blood2 citations Open access
Semantic Scholar
Individual molecular response evaluation on both DNA and mRNA BCR-ABL1 level diminished differences in time to molecular response achievement between CML patients with E13A2 vs E14A2 transcript type
K. Polakova, M. Salmon, H. Žižková, A. Gottschalk +17 more
20202 citations
Semantic Scholar
A Comparison of Two Standardized Quantitative RT-PCRs with CE IVD Kit for Digital PCR in CML Patients with Different Level of BCR-ABL1 Transcripts
A. Folta, T. Jurček, B. Kubešová, Daniela Žáčková +2 more
2019Blood2 citations Open access
Semantic Scholar
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials
Daniela Žáčková, H. Klamová, J. Mužík, E. Cmunt +8 more
2013Leukemia and Lymphoma2 citations
Semantic Scholar
The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia
K. Skřivanová, M. Bendová, L. Dušek, Daniela Žáčková +2 more
20132 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Mayer×25
Invite
J. Mayer — researcher profile on SciRah
Z. Ráčil×18
Invite
Z. Ráčil — researcher profile on SciRah
T. Jurček×16
Invite
T. Jurček — researcher profile on SciRah
H. Klamová×16
Invite
H. Klamová — researcher profile on SciRah

P. Bělohlávková

×12

Invite

P. Bělohlávková — researcher profile on SciRah

Invite

F. Rázga — researcher profile on SciRah

Katerina Machova Polakova×9

Invite

Katerina Machova Polakova — researcher profile on SciRah

Invite

J. Voglová — researcher profile on SciRah

I. Ježíšková×9

Invite

I. Ježíšková — researcher profile on SciRah

Invite

E. Faber — researcher profile on SciRah

D. Dvorakova×8

Invite

D. Dvorakova — researcher profile on SciRah

P. Cetkovský×8

Invite

P. Cetkovský — researcher profile on SciRah